Insulin-like growth factor (IGF-I) plays an important role during brain development. IGF binding protein-5 (IGFBP-5) is known to be capable of modulating IGF-I actions and is expressed in brain during development. To begin to investigate the interaction between IGF-I and IGFBP-5 in brain, we asked whether IGF-I influences the brain expression of IGFBP-5. We quantified IGFBP-5 expression in multiple brain regions of two lines of IGF-I transgenic (Tg) mice that exhibit distinctive patterns of brain transgene expression. MT-I/IGF-I Tg mice carry a transgene driven by metallothionein-I (MT-I) promoter and exhibit highest levels of transgene expression in cerebral cortex, whereas in IGF-II/IGF-I Tg mice the mouse IGF-II promoter drives the transgene and the expression is highest in the cerebellum. In normal adult mice, IGFBP-5 messenger RNA (mRNA) was detected in all brain regions examined, and the highest levels of the mRNA were found in cerebellum, followed by brainstem, diencephalon, hippocampus, and cerebral cortex. Compared to these littermate controls, IGFBP-5 mRNA abundance was increased in both lines of Tg mice. In MT-I/IGF-I Tg mice, cerebral cortex had the greatest increase (ϳ200%), whereas cerebella of IGF-II/IGF-I Tg mice had the greatest increase in IGFBP-5 mRNA (ϳ350%). The increase in IGFBP-5 mRNA correlated with the regional expression of the transgene during development. The abundance of IGFBP-5 protein was also found to be increased in both IGF-I Tg mouse lines. The influence of IGF-I on IGFBP-5 expression was specific because we found no evidence of changes in IGFBP-2, IGFBP-4, or cyclophilin expression. Furthermore, as judged by in situ hybridization histochemistry, IGF-I appeared to increase both the number of IGFBP-5-expressing cells and the magnitude of their expression, an observation that was especially marked in the molecular layer and white matter of the cerebellum. These data indicate that IGF-I regulates IGFBP-5 expression in vivo and is consistent with the in situ hybridization data of others showing that IGFBP-5 expression is temporally and spatially related to that of IGF-I. (Endocrinology 139: [65][66][67][68][69][70][71] 1998) 
IGFBP-5 mRNA abundance was increased in both lines of Tg mice. In MT-I/IGF-I Tg mice, cerebral cortex had the greatest increase (ϳ200%), whereas cerebella of IGF-II/IGF-I Tg mice had the greatest increase in IGFBP-5 mRNA (ϳ350%). The increase in IGFBP-5 mRNA correlated with the regional expression of the transgene during development. The abundance of IGFBP-5 protein was also found to be increased in both IGF-I Tg mouse lines. The influence of IGF-I on IGFBP-5 expression was specific because we found no evidence of changes in IGFBP-2, IGFBP-4, or cyclophilin expression. Furthermore, as judged by in situ hybridization histochemistry, IGF-I appeared to increase both the number of IGFBP-5-expressing cells and the magnitude of their expression, an observation that was especially marked in the molecular layer and white matter of the cerebellum. These data indicate that IGF-I regulates IGFBP-5 expression in vivo and is consistent with the in situ hybridization data of others showing that IGFBP-5 expression is temporally and spatially related to that of IGF-I. (Endocrinology 139: 65-71, 1998) I NSULIN-LIKE growth factor I (IGF-I) plays an important role in the development of central nervous system (CNS) (1) . Using transgenic (Tg) mice that overexpress IGF-I in brain as a model, we have previously demonstrated that IGF-I promotes proliferation and/or survival and maturation of neurons and their precursors (2, 3) . We also have demonstrated that IGF-I increases oligodendrocyte number and stimulates their capacity to produce myelin (4, 5) .
IGF-I's actions are modulated by a family IGF binding proteins (IGFBP; IGFBP-1 to IGFBP-6). IGFBP-5 is abundantly expressed in brain. Its expression is maximal in first two weeks of postnatal life (6 -8) and occurs in a spatotemporal pattern that coincides with the expression of brain IGF-I (8 -10) . In addition, brain IGFBP-5 expression is often associated with the proliferation of neural precursors, as in external granular layer of cerebellum and in paraventricular zone. These data led us to postulate that IGF-I regulates the expression of IGFBP-5, which may in turn augment IGF-I's actions in brain development in an autocrine or paracrine fashion.
To begin to test our hypothesis, we have examined the expression of IGFBP-5 in two distinct lines of IGF-I Tg mice: metallothionein-I (MT-I)/IGF-I and IGF-II/IGF-I Tg mice. The MT-I/IGF-I Tg mice, in whom the transgene is driven by a mouse MT-I promoter, exhibit the highest levels of IGF-I transgene expression in cerebral cortex, (followed by hippocampus Ͼ diencephalon Ͼ brainstem and cerebellum; Ref 4) . The IGF-II/IGF-I Tg mice, whose transgene is directed by a mouse IGF-II promoter, have the highest transgene expression in cerebellum, followed by brainstem and diencephalon, hippocampus, and cerebral cortex (2) . Our studies show that the steady-state levels of IGFBP-5 messenger RNA (mRNA) are increased in the brains of IGF-I Tg mice, compared with those of normal littermate controls. These increases in IGFBP-5 mRNA abundance correlate with the expression of transgenes and are due to increases in the number of expressing cells, as well as increased expression in individual cells. Furthermore, IGFBP-5 polypeptide was increased in IGF-I Tg mice. These data indicate that IGF-I up-regulates brain IGFBP-5 expression in vivo at both the mRNA and protein levels.
Materials and Methods

Transgenic mice
Generation of MT-I/IGF-I and IGF-II/IGF-I Tg mice has been described elsewhere (2, 4) . Both types of Tg mice were bred as heterozygotes and routinely identified by PCR of tail genomic DNA, using 20-mer oligonucleotide primers identical to human IGF-I cDNA sequence. Mice were maintained with 12-h light, 12-h dark cycles at 22C. All procedures used were approved by institutional review committee of the University of North Carolina at Chapel Hill.
Northern blot hybridization analysis
Total RNA was extracted from various brain regions using the acidic guanidinium thiocyanate-phenol-chloroform method (11) and quantified spectrophotometrically at 260 nm. Aliquots of 20 g total RNA were electrophoresed on 1% agarose gels, transferred onto a GeneScreen membrane (DuPont-NEN, Boston, MA) and UV cross-linked. After stained with 0.02% methylene blue and photography to quantify the amount of RNA transferred, the membranes were hybridized with radiolabeled single stranded DNA (ssDNA) probes (see below) in Church's buffer (0.5 m sodium phosphate, pH 7.1/7%, SDS/0.1 mm EDTA), and specific message bands were detected by autoradiography. After autoradiography, membranes were stripped in 20 mm sodium phosphate/0.5 mM EDTA at 80 -85C for 30 -60 min and hybridized with a second probe.
Quantification was performed using a computer-assisted image analysis system (Image-Pro, Media Cybermetics, Silver Spring, MD). To ensure the accuracy of the changes in mRNA abundance and equal loading of RNA, the message levels were normalized to the cyclophilin (CYC) mRNA abundance or to the amount of 18S rRNA on the membrane. The abundance of CYC mRNA closely paralleled the amount of 18S rRNA transferred, as estimated by methylene blue staining.
Probes
IGFBP-5, CYC, and IGF-I DNA fragments were PCR amplified and used as templates for probes. The IGFBP-5 DNA fragment corresponded to bp 558-1201 of rat IGFBP-5 cDNA (12), CYC DNA fragment corresponded to bp 106-517 of the rat CYC cDNA (13) , and IGF-I DNA fragment corresponded to bp 179-537 of human IGF-I cDNA (14) . ssDNA probes were generated from these templates by linear PCR using their respective 3Ј end primers and 32 P-labeled deoxy-CTP (Amersham, Arlington Heights, IL), as previously reported (15, 16) .
I-IGF-I ligand and Western blot analysis
Brains of Tg and normal littermate mice were dissected and frozen in liquid nitrogen. To extract protein, about 50 mg frozen tissue was pulverized, lysed, and sonicated in lysis buffer (20 mm Tris-HCl, pH 7.4, 2% Triton X-100 and 10 mm EDTA). Supernatants were collected by centrifugation at 12,000 rpm in a microcentrifuge for 5 min at 4C. Aliquots of 80 g protein were separated on 12.5% polyacrmide gel and transferred onto nitrocellulose membrane (Schleicher & Schuell, Keene, NH). For ligand blot analysis, membranes were incubated with a ligand hybridization buffer containing 125 I-IGF-I (5 ϫ 10 5 cpm/ml), as previously described (17) . Western blot analysis was performed using a chemiluminescence Western blotting kit (Boehringer Mannheim, Indianapolis, IN) and a polyclonal anti-IGFBP-5 antibody (1:500, provided by Dr. David Clemmons, University of North Carolina), according to the manufacturer's protocol.
In situ hybridization histochemistry (ISHH)
ISHH was performed as previously described (4) . Briefly, after fixation with 4% paraformaldehyde in PBS, the sagittal frozen-sections (10 m) were treated with 0.2 n HCl, extensively washed with PBS and hybridized with IGFBP-5 antisense digoxigenin-riboprobe generated using Genius RNA Labeling kit (Boehringer Mannheim, Indianapolis, IN). The hybridization buffer contained 75% formamide, 10% dextran sulfate, 3 ϫ SSC, 1 ϫ Denhart's, 50 mm sodium phosphate, pH 7.4, and approximately 0.5 ng/l of the probe. After incubation with the probe for 16 -18 h at 55 C, the sections were washed with 2 ϫ SSC and 1 ϫ SSC at 55 C, followed by a wash with 0.2 ϫ SSC for 1 h at 55C. The sites of IGFBP-5 mRNA were revealed by incubating with antidigoxigenin antibody conjugated with alkaline phosphatase (1:250) and 5-bromo-4-chloro-3-indolyl phosphate with nitroblue tetrazolium at room temperature. Liver, which expresses little IGFBP-5 (Ref. 18 and our unpublished data), was used as a negative control.
Statistics
Statistic comparisons were made using the Student's t test.
Results
A single approximately 6 kb of IGFBP-5 transcript was detected by Northern blot hybridization analysis of all brain regions examined (Fig. 1) . In normal adult mice, cerebellum exhibited the highest levels of IGFBP-5 mRNA, followed by diencephalon, brainstem, hippocampus, and cerebral cortex. Compared with their normal littermates, the abundance of IGFBP-5 mRNA was significantly increased in most brain regions of both lines of IGF-I Tg mice. In MT-I/IGF-I Tg mice, cerebral cortex exhibited the greatest increase in IGFBP-5 mRNA abundance (by ϳ92% over control, P Ͻ 0.05), fol- lowed by hippocampus (ϳ63%, P Ͻ 0.05), and brainstem (ϳ50%, P Ͻ 0.05) (Figs. 1A and 2, top panel). Diencephalon and cerebellum also exhibited ϳ67% and ϳ14% increases, respectively, but these increases were not significant. In IGF-II/IGF-I Tg mice cerebellum had the greatest increase in IGFBP-5 mRNA abundance (by ϳ254%, P Ͻ 0.01), followed by brainstem (ϳ137%, P Ͻ 0.05) and cerebral cortex (ϳ58%, P Ͻ 0.01) (Figs. 1B and 2, bottom panel) . Diencephalon showed an approximately 149% increase in IGFBP-5 mRNA, but this was not significant because of high variation among animals. These regional increases in brain IGFBP-5 expression in the IGF-I Tg mice correspond to the magnitude of IGF-I transgene expression that we have found in these brain regions (2, 4) .
To verify that the spatial expression of IGF-I transgenes in the Tg mice used in these experiments was similar to those previously reported by us (2, 4), we rehybridized membranes with probes specific for our transgenes. Consistent with our previous data, a single band of MT-I/IGF-I transgene mRNA at approximately 0.9 kb and multiple sizes of IGF-II/IGF-I transgene mRNA at approximately 0.9, 1.2, and 2.8 kb were observed (Fig. 1) . The expression of the transgenes again exhibited a similar regional pattern and correlated with the increase in IGFBP-5 mRNA abundance (Figs. 1 and 3) . In MT-I/IGF-I Tg mice, the highest levels of IGF-I transgene expression were found in cerebral cortex, followed by hippocampus (ϳ100% of cerebral cortex), diencephalon (ϳ30%), brainstem (ϳ25%), and cerebellum (ϳ6%). While IGF-II/ IGF-I Tg mice had the highest transgene expression in cerebellum, followed by brainstem (ϳ26% of cerebellum), diencephalon (ϳ23%), cerebral cortex (ϳ21%), and hippocampus (ϳ2%).
To further examine the dependence of IGFBP-5 expression on the IGF-I transgene expression, we examined the IGFBP-5 transcripts during development by Northern blot hybridization analysis of the cerebral cortex and the cerebella from MT-I/IGF-I and IGF-II/IGF-I Tg mice, respectively. These regions were selected because they exhibit the highest levels of transgene expression and the greatest increase in IGFBP-5 mRNA abundance in each line. In the normal mice, the steady-state level of IGFBP-5 mRNA in cerebral cortex was high at postnatal day (P) 7, the earliest time examined, then fell by 4-and 5-fold at P21 and P42, respectively (Fig. 4, top  panel) . In contrast, the abundance of IGFBP-5 mRNA in cerebellum only modestly decreased during development and the changes were not significant (Fig. 4, bottom panel) . Compared with their normal littermates, however, the abundance of IGFBP-5 mRNA gradually increased both in the cerebral cortex of MT-I/IGF-I Tg mice and in the cerebellum of IGF-II/IGF-I Tg mice, reaching about 200 -300% of normal levels at P42 (Fig. 4) . In contrast, the abundance of IGFBP-2 and IGFBP-4 mRNAs in MT-I/IGF-I Tg mice did differ from their normal littermate (data not shown).
To determine whether the increases in IGFBP-5 mRNA levels in brain were due to an increase in the number of expressing cells or due to increased expression in individual cells, we performed in situ hybridization histochemistry (ISHH) to determine the sites and approximate quantity of IGFBP-5 mRNA expression. Consistent with our Northern blot hybridization and the ISHH data of others (6, 8) , IGFBP-5 mRNA was detected in all major brain regions of P42 normal and Tg mice, and most labeled cells were neurons, as judged by morphologic criteria. Representative microphotographs of in situ hybridization for IGFBP-5 mRNA in cerebral cortex, hippocampus, and cerebellum are shown in Fig. 5 . In normal mice, large and modestly stained IGFBP-5 positive cells were evenly distributed throughout the cerebral cortex (Fig. 5A) . In hippocampus dentate gyrus neurons were also modestly stained (Fig. 5C ). Purkinje cells and internal granular cells were the major cerebellar cells expressing IGFBP-5, but molecular layer cells and white matter cells also expressed low levels of IGFBP-5 (Fig. 5E) . Consistent with our unpublished Northern data and the data of others (18), liver exhibited little IGFBP-5 signal (Fig. 5G) . Compared with normal littermate controls, the intensity of the signal and the number of labeled cells were significantly increased in the IGF-I Tg mice (Fig.  5, B, D, and F) . This was particularly evident in the CB of IGF-II/IGF-I Tg mice where the expression of IGFBP-5 in molecular layer and white matter cells was much more prominent (Fig. 5E) .
To determine whether IGFBP-5 protein also was increased in the brains of Tg mice, we performed Western ligand blot analysis using extracts from cerebral cortex of MT-I/IGF-I Tg mice and cerebella of IGF-II/IGF-I Tg mice, the two regions with the greatest increase in IGFBP-5 mRNA. In normal cerebral cortex, IGF-I binding proteins of approximately 24 and 32 kDa were detected, whereas in cerebellum a 32-kDa protein was the major protein observed (Fig. 6A) , but a 24-kDa IGFBP was observed after extended exposure (data not shown). Compared with their littermate controls, cerebral cortex of MT-I/IGF-I Tg mice exhibited a marked increase in the abundance of 32-kDa IGFBP (ϳ3.2-fold greater than controls, P Ͻ 0.01) but not in the 24-kDa IGFBP (Figs. 6A and 7) . Similarly, the amount of 32 kDa was increased in the cerebella of IGF-II/IGF-I Tg mice (by ϳ2-fold, P Ͻ 0.05) (Figs. 6A  and 7) .
Because both IGFBP-5 and IGFBP-2 migrate with similar molecular mass (ϳ32 kDa), we employed Western immunoblot to confirm that the changes observed in Western ligand blot analysis were due to the changes in the IGFBP-5 abundance. Normal serum, which contains little, if any, IGFBP-5, but abundant IGFBP-2 and -4, exhibited no immunoreactive signal (Fig. 6B) . In both normal and IGF-I Tg mice, a single band of 32 kDa was observed in cerebral cortex (Fig.  6B) . In cerebellum, however, an additional band with a molecular weight slightly larger than 32 kDa was observed. Consistent with the results of Western ligand blot analysis, the abundance of IGFBP-5 was significantly increased in cerebral cortex of MT-I/IGF-I Tg mice (by ϳ2.5-fold, P Ͻ 0.01), as compared with normal controls (Fig. 6B and Fig. 8 ).
In the cerebellum of IGF-II/IGF-I Tg mice, both bands of approximately 32 kDa were increased in abundance ( Fig. 6B  and 8 ), and when we combined the abundance of both bands, cerebellar IGFBP-5 abundance was increased by approximately 2.1-fold (P Ͻ 0.01).
Discussion
Our data indicate that IGF-I stimulates the expression of brain IGFBP-5 in vivo. As compared with the brain of littermate controls, IGFBP-5 mRNA and protein are increased in the brains of both MT-I/IGF-I and IGF-II/IGF-I Tg mice in a spatial pattern and temporal that correlates with the regional and developmental expression of the IGF-I transgenes. As judged by ISHH, the increases in the expression of IGFBP-5 mRNA are due to increases in both the number of expressing cells, as well as its expression in individual cells.
The up-regulation of IGFBP-5 gene expression by IGF-I appears to be specific because we did not observe changes in the abundance of mRNAs for IGFBP-2, IGFBP-4, or cyclophilin. Similarly, the abundance of IGFBP-4 protein (presumed to be the 24-kDa band) did not differ in the cerebral cortex of IGF-I Tg mice and normal controls. Similar results also were observed in cultured aortic smooth muscle cells (19) and in thyroid cell line (20) . Duan et al. (19) showed that addition of IGF-I to culture medium greatly stimulates the synthesis of IGFBP-5, but not IGFBP-2, in a dose-and timedependent manner. This stimulation of IGFBP-5 expression by IGF-I appears to be cell specific because IGF-I increases IGFBP-5 mRNA abundance in both cultured porcine and human aortic smooth muscle cells but not human intestinal smooth muscle and fetal skin fibroblasts. Our ISHH data suggest that most IGFBP-5 expressing cells are affected. Whether the expression of IGFBP-5 in a subgroup of neurons and other IGFBP-5 expressing cells is not regulated by IGF-I, however, remains to be determined.
The regional IGFBP-5 expression in mouse brain has not been quantitatively analyzed previously. We found that the highest level of IGFBP-5 mRNA was expressed in the cerebellum of normal adult mice, followed by brainstem, diencephalon, hippocampus, and cerebral cortex. Similar results were observed in rat (6) . ISHH analysis of cerebellum shows that Purkinje cells and internal granular cells are major cells expressing IGFBP-5 mRNA, whereas molecular layer cells and white matter cells express low levels of IGFBP-5 mRNA. Identification of the cells expressing IGFBP-5 in molecular layer and white matter may provide clues to IGFBP-5 actions. Bondy and Lee (8) , using ISHH, showed that IGFBP-5 mRNA is transiently expressed in external granular cells during early cerebellum development. This expression, however, disappears with the inward migration of cells, and gradually increases in internal granular cells layer (Golgi cells) with age. In addition, they did not observe Purkinje cell IGFBP-5 expression. Stenvers et al (6) , also using ISHH, did not detect a IGFBP-5 signal in either cerebral cortex or hippocampus in adult rat, although they demonstrated high expression of IGFBP-5 in both regions by Northern blot hybridization. Therefore, our data show a distinctive distribution pattern of IGFBP-5 expression in mouse brain that differs somewhat from these reports in the rat brain. The discrepancies may reflect a species-specific expression of brain IGFBP-5, or alternatively, a different sensitivity of the method employed.
Previous reports indicate that the expression of IGFBP-5 is temporally and spatially correlated to IGF-I mRNA expression during brain development (8 -10) . Consistent with the known developmental decrease in IGF-I mRNA levels in cerebral cortex, our data show that the expression of IGFBP-5 mRNA also gradually decreases with age in the cerebral cortex of normal mice. We, however, observed no such decrease in cerebellar IGFBP-5 mRNA during development, despite decreases in the IGF-I mRNA levels during this same time period (10, 21) . The high levels of IGFBP-5 mRNA in cerebella, however, are likely explained by relatively stable IGF-I protein content in developing cerebellum. ToreesAleman et al. (21) observed little change in rat cerebellar IGF-I content during development despite the fall of cerebellar IGF-I mRNA. Transport of IGF-I to the cerebellum from the inferior olives appears to explain the stable levels of cere- bellar IGF-I (22) , and in turn the relatively high and stable abundance of IGFBP-5 mRNA during development that we observed.
IGFBP-5 is capable of potentiating IGF-I's actions on cell proliferation and growth in culture. When IGFBP-5 is associated with extracellular matrix, it can augment IGF-I's actions on fibroblast growth (23). Andress and Birnbaum (24) showed that osteoblast-derived IGFBP-5 potentiates the stimulatory effects of IGF-I or IGF-II on mitogensis of cultured osteoblasts. Consistent with these in vitro data, high levels of IGFBP-5 expression is often found coincident with IGF-I expression and with cellular proliferation in the developing brain (8) . High IGFBP-5 expression also has been found in the cerebellum of the Weaver mutant mice (25) and in the areas surrounding lesions during recovery from hypoxia-ischmia injury (26) . In this study, we have further demonstrated that IGF-I up-regulates the expression of brain IGFBP-5 in vivo, supporting our hypothesis that IGFBP-5 plays an important role in augmenting IGF-I's stimulatory actions on CNS development.
